A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata

Last updated: December 6, 2013
Sponsor: The Hospital for Sick Children
Overall Status: Completed

Phase

3

Condition

Hair Loss

Alopecia

Treatment

N/A

Clinical Study ID

NCT01453686
0020020248
  • Ages 2-16
  • All Genders

Study Summary

The use of topical steroids in the treatment of alopecia areata in children is common practice. However, no particular potency of steroid is accepted as the standard treatment due to the paucity of high quality evidence in the dermatology literature to substantiate their use. Two randomized controlled trials exist assessing topical steroid efficacy in this disorder, both have methodological limitations. The question remains as to which topical steroid is safe and efficacious for use. We performed a double blinded controlled trial to assess the usefulness of a class 1 topical steroid (clobestasol proprionate 0.05%) compared with a class 7 topical steroid (hydrocortisone 1%) in children with alopecia areata.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 2 to 16 years

  • New patients presenting to The Hospital for Sick Children

  • Clinical confirmation of alopecia areata

  • Hair loss between 10 -75%

Exclusion

Exclusion Criteria:

  • Skin or medical problems requiring use of oral steroids

  • Immunosuppressants or PUVA for 4 weeks prior to the study

  • Use of inhaled and or intranasal steroids for 14 days prior to trial

  • Topical medicaments for 7 days prior to the trial

Study Design

Total Participants: 41
Study Start date:
August 01, 2002
Estimated Completion Date:
August 31, 2003

Connect with a study center

  • The Hospital for Sick Children

    Toronto, Ontario M5G 1X8
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.